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The cut-off point of intrahepatic triglyceride (IHTG) content to define nonalcoholic fatty liver disease (NAFLD) by proton magnetic resonance spectroscopy ( 1 H-MRS) was established based on the 95th percentile in a group of healthy individuals (i.e., !5.56%). Whether this threshold correlates with metabolic and histological changes and whether a further accumulation of IHTG is associated with worsening of these parameters has not been properly assessed in a large cohort of patients. In this cross-sectional study, 352 subjects were carefully characterized with the following studies: liver 1 H-MRS; euglycemic insulin clamp with measurement of glucose turnover; oral glucose tolerance test; and a liver biopsy. Hepatic insulin sensitivity (suppression of endogenous glucose production by insulin) was affected early on after IHTG content was $1.5% and remained uniformly impaired ($40%-45%), regardless of further IHTG accumulation. Skeletal muscle insulin sensitivity showed a gradual impairment at low degrees of IHTG accumulation, but remained unchanged after IHTG content reached the $6 6 2% threshold. A similar pattern was observed for metabolic changes typically associated with NAFLD, such as hypertriglyceridemia and low high-density lipoprotein cholesterol (HDL-C). In contrast, adipose tissue insulin sensitivity (suppression of free fatty acids by insulin) showed a continuous worsening across the spectrum of IHTG accumulation in NAFLD (r 5 -0.38; P < 0.001). Histological severity of liver disease (inflammation, ballooning, and fibrosis) was not associated with the amount of IHTG content. Conclusion: IHTG accumulation is strongly associated with adipose tissue insulin resistance (IR), supporting the current theory of lipotoxicity as a driver of IHTG accumulation. Once IHTG accumulation reaches $6 6 2%, skeletal muscle IR, hypertriglyceridemia, and low HDL-C become fully established. Histological activity appears to have an early threshold and is not significantly influenced by increasing amounts of IHTG accumulation. (HEPATOLOGY 2017; 65:1132 -1144 ).
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N onalcoholic fatty liver disease (NAFLD) encompasses a wide range of liver disease that ranges from a relatively benign intrahepatic triglyceride (IHTG) accumulation to severe inflammation and necrosis, leading to cirrhosis and hepatocellular carcinoma. (1, 2) It is generally accepted that the presence of visible steatosis in >5% of hepatocytes assessed by light microscopy constitutes a fatty liver. (1, 2) In a landmark study by Szczepaniak et al., (3) a group of 345 patients without any risk factors for hepatic steatosis was used to establish a threshold to define fatty liver using proton magnetic resonance spectroscopy ( 1 H-MRS). Based on the 95th percentile of IHTG content for this "normal" population, the threshold of 5.56% was originally defined. (3) However, in this study normal was defined as lean (<25 kg/m 2 of body mass index [BMI]), without type 2 diabetes mellitus (T2DM), with normal fasting plasma glucose (FPG), and normal plasma alanine aminotransferase (ALT). Therefore, it is likely that this cohort included patients not metabolically healthy based on results from an oral glucose tolerance test (e.g., patients with severe insulin resistance [IR] or prediabetes), blood pressure measurements, and/or lipid measurements (patients with high triglycerides [TGs] and low HDL-C). This would have resulted in an overestimation of the real cutoff point to define normality.
After more than 10 years since its original description, this cut-off point still remains widely accepted when defining NAFLD by liver 1 H-MRS and is frequently used by our group and others. (4) (5) (6) However, whether this population-based cut-off point reflects the threshold of IHTG content associated with metabolic and/or histological changes in patients with NAFLD remains unclear. Moreover, it is also unknown whether a greater accumulation of IHTG beyond this "threshold" of 5.56% further worsens the metabolic or histological profile of these patients.
Therefore, the aim of the current study was to establish the threshold of IHTG content at which metabolic and histological changes occur in mainly overweight and obese patients.
Patients and Methods

SUBJECTS
A total of 352 subjects were recruited from newspaper advertisements, as well as endocrinology and hepatology clinics in Gainesville, Florida, and San Antonio, Texas. Patients underwent a complete medical history, physical exam, and routine chemistries as part of the screening process. Subjects were excluded if they had a history of significant alcohol consumption (!30 g/day in males and !20 g/day in females), or severe heart, pulmonary, and/or renal disease. Among patients with a diagnosis of T2DM, only stable doses of metformin, sulphonylureas, and/or insulin were allowed. Patients with other causes of liver disease (viral hepatitis, autoimmune hepatitis, Wilson's disease, hemochromatosis, drug-induced hepatitis, or others) were excluded. Patients with a histological diagnosis of cirrhosis were also excluded from the study, given that liver fat content has been shown to be reduced in these patients. (7) Informed written consent was obtained from each patient before participation, and the study was approved by the institutional review boards from both universities (University of Florida and University of Texas Health Science Center at San Antonio). Patients reported on in this work have been previously included in other articles in relationship to the role of ethnicity (8) and different metabolic variables in NAFLD/nonalcoholic steatohepatitis (NASH), (4, (9) (10) (11) (12) and the use of liver ultrasound for the diagnosis of NAFLD. 
STUDY DESIGN
In this cross-sectional study, all patients underwent a liver 1 H-MRS to quantify IHTG content, in addition to the following metabolic measurements: (1) FPG, insulin, and free fatty acids (FFAs), hemoglobin A1c (HbA1c), lipid profile, and plasma aminotransferase levels; (2) 2-hour oral glucose tolerance test (OGTT) to establish the diagnosis of T2DM according to the American Diabetes Association criteria (13) and to calculate insulin resistance, secretion, and clearance (11) ; (3) total body fat (TBF) by dual-energy x-ray absorptiometry (DXA); and (4) 
H-MRS
Localized proton nuclear magnetic resonance spectra of the liver was acquired using methodology previously described. (5) Three different locations of the liver of 30 3 30 3 30 mm each were selected avoiding vessels and bile ducts. Liver fat content was calculated as fat fraction (area under the curve [AUC] fat peak/[AUC fat peak 1 water peak]) using commercial software (NUTS, Acorn NMR). Measurements were corrected for T1 and T2 relaxation as previously described. (14) Euglycemic Hyperinsulinemic Clamp
After an overnight fast, subjects were studied at the research unit as previously described (11, 15) with the infusion of 3- ] glucose (DuPont-NEN, Boston, MA) was initiated and continued until the end of the study. After the basal equilibration period, insulin was administered as a primed-continuous infusion at 10 mIU/ (m 2 Á minute) for 120 minutes to assess suppression of endogenous glucose production (EGP), followed by another 2 hours at an infusion rate of 80 mIU/(m 2 Á minute) for 120 minutes to assess skeletal muscle insulin-stimulated glucose disposal (Rd). A variable infusion of 20% glucose was adjusted based on the negative feedback principle to maintain the plasma glucose concentration at approximately 90-100 mg/dL with a coefficient of variation <5%.
Liver Biopsy
An ultrasound-guided liver biopsy was performed in patients with a diagnosis of NAFLD on 1 H-MRS. Biopsies were evaluated by a pathologist that was unaware of the subjects' identity or clinical information. Histological characteristics for the diagnosis of NASH were determined using standard criteria. (16, 17) CALCULATIONS EGP and Rd were calculated using non-steady-state equations as previously reported. (15) Suppression of EGP and FFAs by low-dose insulin were calculated during the euglycemic clamp to account for hepatic (HIR) and adipose tissue insulin resistance (ATIR), respectively, during nonfasting (i.e., insulin infusion) conditions. To estimate hepatic insulin clearance, we used the incremental C-peptide/insulin AUC (molar) ratio calculated by the trapezoidal rule during the OGTT, as described before.
(11)
ANALYTICAL METHODS
Plasma C-peptide and insulin were measured by radioimmunoassay, with plasma FFAs by standard colorimetric methods. HbA1c was measured by highperformance liquid chromatography (TOSOH G-7). Plasma glucose radioactivity was measured from deproteinized plasma samples precipitated from barium hydroxide/zinc sulfate. (15) 
STATISTICAL ANALYSIS
All values are reported as the mean 6 SD of the mean for continuous variables and the number (percent) for categorical variables. Linear Pearson's correlations were performed for individual data points without consideration of quantile groups (even when trend lines were represented within bar graphs for clarity). Threshold points for biphasic associations were established by identifying the lowest IHTG content that differentiated between the two ß coefficients (slopes), provided that the first ß coefficient was statistically significant and the second one was not statistically different from 0 (implying no further correlation between IHTG and the dependent variable). Overall comparisons among quantiles were performed using nonparametric tests for trend across ordered groups based on Wilcoxon's rank-sum test. A P value of <0.05 (two-tailed) was considered statistically significant. All statistical calculations were performed using Stata software (version 11.1; StataCorp LP, College Station, TX), and graphs were performed with Prism software (version 6.0; GraphPad Software Inc., La Jolla, CA).
Results
SUBJECT CHARACTERISTICS AND QUANTILES OF IHTG CONTENT
Patients' clinical characteristics are summarized in Table 1 . As can be observed, this cohort included patients who were middle aged, mainly overweight and obese (mean BMI, 33.1 6 5.3 kg/m 2 ), and with an elevated risk for NAFLD, based on high prevalence of T2DM (61% of the cohort), severe IR based on homeostasis model assessment of insulin resistance (HOMA-IR; 3.9 6 3.9) or adipose tissue insulin resistance (5.8 6 6.0 lIU/mL • mmol/L), and high frequency of elevated plasma aminotransferases (40%). The proportion of patients with NAFLD by 1 H-MRS in the overall population was 64%. No differences were observed between the San Antonio, Texas, and the Gainesville, Florida cohorts regarding demographic, clinical, metabolic, and histological data.
Clinical characteristics of patients with versus without T2DM are also compared in Table 1 . Of note, patients with T2DM were well controlled based on relatively low HbA1c (7.1%), and many of these patients were only diagnosed with T2DM with the OGTT performed as part of the study. As can be observed, FPG, HbA1c, histological inflammation, and hepatic fibrosis stage were different between these groups. No difference was observed in the prevalence of NAFLD between patients with and without T2DM (64% and 65%; P 5 0.88) or in the quantification of IHTG content by 1 H-MRS between these two groups. No significant differences were observed in BMI, total adiposity by DXA, or plasma aminotransferases.
Patients were then divided in 10 quantiles (i.e., deciles) based on IHTG content measured by 1 H-MRS. Cut-off points that determined the 10 groups were as follows: quantile 1 (<1.5%); quantile 2 (1.5%-2.7%); quantile 3 (2.8%-4.1%); quantile 4 (4.2%-6.5%); quantile 5 (6.6%-8.4%); quantile 6 (8.5%-11.1%); quantile 7 (11.2%-14.1%); quantile 8 (14.2%-17.1%); quantile 9 (17.2%-22.4%); and quantile 10 (>22.4%). Of note, no significant differences were observed in total adiposity by DXA (31%, 34%, 34%, 33%, 36%, 34%, 35%, 34%, 34%, and 35%, respectively), prevalence of T2DM (from 44% to 77%; P 5 0.64), or use of specific medications, such as metformin (from 29% to 55%; P 5 0.37), sulphonylureas (from 9% to 41%; P 5 0.12), insulin (from 9% to 18%; P 5 0.98), and/or statins (from 43% to 71%; P 5 0.10), among the groups.
IHTG CONTENT AND INSULIN SENSITIVITY
In Fig. 1 , we have summarized the effect of increasing IHTG content on IR at the levels of the liver and skeletal muscle. As can be observed, hepatic insulin sensitivity, measured as suppression of EGP by lowdose insulin infusion, appeared blunted after only a small TG accumulation in the liver (quantile 2), but then remained constant ($40%-45%) regardless of the amount of IHTG content (Fig. 1A) . The calculated threshold at which suppression of EGP found a plateau was 1.5%. In accord with this, we observed no association between hepatic insulin sensitivity and IHTG content in patients from quantiles 2 to 10 (r 5 0.03; P 5 0.77). Insulin sensitivity in skeletal muscle (Rd) showed a less-steep, more-progressive reduction with increasing IHTG content up to quantile 4 (4.2%-6.5%; r 5 -0.65; P < 0.001), reaching a plateau when IHTG content was in the range of quantile 5 (r 5 0.12; P 5 0.27; Fig. 1B ).
In accord with the graph, a calculation of the IHTG threshold showed that Rd reached a plateau after a IHTG content of 4.2% (ß 5 0.004; P 5 0.90).
In contrast, there was a gradual reduction of suppression of plasma FFAs by low-dose insulin infusion with increasing IHTG content across the whole spectrum of IHTG (Fig. 2) . This resulted in a significant negative correlation between these two parameters (r 5 -0.38; P < 0.001), with no clear "threshold" of IHTG content being associated with an abrupt impairment in adipose tissue insulin sensitivity. 
RELATIONSHIP BETWEEN HYPERINSULINEMIA AND IHTG CONTENT
Increasing accumulation of IHTG was associated with continuous reduction in hepatic insulin extraction, as observed in Fig. 3A . Likely as a result of this impairment, we observed a step-wise increase in plasma fasting insulin levels with increasing IHTG accumulation ( Fig.  3B ; r 5 0.33; P < 0.001). This correlation occurred in both patients with T2DM (r 5 0.31; P < 0.001) and those without T2DM (r 5 0.37; P < 0.001), as detailed in Supporting Fig. S1 . In line with similar suppression of EGP from quantiles 2 to 10, FPG was no different among these quantiles (Fig. 3C) . A similar progression of FPG was observed along the quantiles in patients with or without T2DM (Supporting Fig. S1 ) or when HbA1c was assessed (Supporting Fig. S2 ).
HOMA-IR (derived from the multiplication of FPG and insulin) followed the same pattern as the one observed for fasting plasma insulin, given that plasma glucose was similar across the quantiles. Moreover, the pattern was similar for patients with and without diabetes (Supporting Fig. S1 ).
METABOLIC IMPACT OF IHTG CONTENT
In order to determine the relationship of IHTG accumulation with metabolic risk in our cohort, different metabolic measurements were assessed across the different quantiles. No differences were found in systolic or diastolic blood pressure among the groups (P 5 0.19 and P 5 0.23), although quantile 1 showed a lower use of hypertension medication than the rest of the quantiles (34% vs. 56%-83%; P 5 0.003). Worsening dyslipidemia with increasing IHTG content, especially increasing hypertriglyceridemia and low HDL-C, was however observed (Fig. 4A,B) . Changes in both plasma TGs and HDL-C along quantiles appeared to plateau after quantiles 5-6. The calculated plateau for plasma TGs was reached at 8.1% of IHTG, whereas for plasma HDL-C concentration the plateau was 8.8% of IHTG. In line with these results, both plasma TGs and HDL-C were well correlated with IHTG content when patients in quantiles 1-5 were included (r 5 0.33, P < 0.001; and r 5 -0.36, P < 0.001, respectively). Neither plasma TG nor HDL-C were correlated with IHTG content in quantiles 6-10 (r 5 0.09, P 5 0.07; and r 5 -0.07, P 5 0.72). Among patients not taking a statin, plasma low-density lipoprotein cholesterol (LDL-C) showed no association with the amount of IHTG (Supporting Fig. S3 ).
RELATIONSHIP BETWEEN IHTG CONTENT AND HISTOLOGY
In order to assess whether IHTG accumulation could be a driver of inflammation, ballooning, and fibrosis in patients with NAFLD, we assessed histological grades and stages among the different quantiles of IHTG content. Patients in quantiles 1-3 (and most of quantile 4) did not undergo a liver biopsy because of their negative 1 H-MRS (i.e., <5.56%). Inflammation, ballooning, and fibrosis were not individually associated with the amount of IHTG content in patients with NAFLD (Fig. 5) . The only exception is that there appeared to be an increase in severity of inflammation between patients on quartile 4 versus the rest of the quartiles (P 5 0.03). Similar results were obtained when the same analysis was repeated for only those patients with a diagnosis of definite NASH or when the percentage of patients in each grade or stage were represented among quantiles (Supporting Fig. S4) .
Regardless of the lack of association between IHTG quantiles and the severity of liver histology, IHTG increase was associated with a linear increase in plasma ALT and aspartate aminotransferase (AST) as observed in Fig. 6 . 
Discussion
This study assessed the metabolic and histological characteristics associated with increasing amounts of IHTG content in a large cohort of patients (n 5 352). Appropriate understanding of the role of IHTG accumulation is likely to have important clinical implications for patients with NAFLD. For instance, it may help to determine whether steatosis reduction is an important outcome in itself, or whether the amount of steatosis could assist in the management of these patients. Until now, it has been unclear whether TG accumulation was associated with a "quantitative" effect (i.e., the higher the amount of IHTG, the worse the metabolic profile) or only a "qualitative" (or threshold) effect (i.e., most metabolic parameters are already affected once a certain IHTG content is reached).
The current findings indicate that there is a clear threshold of IHTG content (6 6 2%), after which metabolic changes like muscle IR, hypertriglyceridemia, and low HDL-C are already fully established (Figs. 1B and 4A,B) . Of clinical relevance, further accumulation of IHTG after this threshold does not seem to be associated with more-severe metabolic or histological consequences. This suggests that the current cut-off point for the diagnosis of NAFLD by 1 H-MRS (5.56%) corresponds not only to the epidemiologically determined threshold, but also to a precise "metabolic" cut-off point as a finely tuned "barometer" of metabolic health. However, it should be noted that below this $6% threshold, small changes of liver fat may still be associated with considerable metabolic effects.
In a previous study by Arulanandan et al. (18) the metabolic profiles of patients without NAFLD, patients with NAFLD with IHTG <15.4%, and patients with NAFLD with IHTG >15.4% were compared. The conclusions of the researchers were that increasing IHTG was associated with a worse metabolic profile. However, differences between the two groups with NAFLD were minor (e.g., glucose, 102 6 16 vs. 104 6 25 mg/dL; HDL, 49.5 6 13.1 vs. 49.4 6 20.0 mg/dL) and could have been related to significantly different BMI between groups. By dividing patients in 10 groups (instead of only two) and providing groups that did not have differences in total adiposity by DXA, the above limitations were overcome. The results of the current study demonstrate only minor metabolic differences with increasing IHTG once above a threshold of 6 6 2%.
The linear correlation observed between ATIR and IHTG content (Fig. 2) supports the current theory that NAFLD is mainly driven by dysfunctional adipose tissue and the consequent increase in plasma FFAs (i.e., insulin resistant adipose tissue ! "FFA ! steatosis). (19, 20) Excessive rates of lipolysis and increased FFA supply results in a "lipotoxic" environment, characterized by lipid accumulation in ectopic tissues leading to cellular dysfunction and/or death. (19) This suggests that the therapeutic target to prevent hepatic steatosis may reside in adipose tissue. Recent positive results with pioglitazone (mainly an adipose tissue insulin sensitizer) in a randomized, controlled trial in NASH further supports this hypothesis. (21) Contrary to adipose tissue, hepatic insulin sensitivity was affected early on, after a relatively small accumulation of IHTG ( Fig. 1A ; insulin suppression of EGP being fully impaired once the IHTG content was 1.5%). Further increases in the amount of IHTG were not associated with worse HIR. Nevertheless, when results from the suppression of EGP were compared to HOMA-IR levels (also considered primarily an indicator of liver IR), we observed an apparent contradiction, given that HOMA-IR levels increased with worsening IHTG accumulation (Supporting Fig. S1 ). HOMA-IR was mainly driven by plasma insulin levels, given that there were no differences in FPG among quantiles (Fig. 3B,C) . Whereas in normal conditions an increase in plasma insulin for the same amount of plasma glucose would suggest IR (the principle in which the HOMA-IR is based), that is not the case when there is impairment of hepatic insulin clearance (Fig. 3A) . As a result of this impairment, venous plasma insulin levels do not represent the levels of insulin reaching the liver (i.e., portal insulin), but only insulin levels remaining after the first hepatic pass. Therefore, if the amount of insulin cleared by the liver is different, plasma insulin levels will also be different without implying a different IR. The association observed in this study between impaired hepatic insulin extraction and IHTG accumulation goes in line with previous findings by our group. (11) Taken together, our interpretation of this apparent discrepancy is that HOMA-IR is a poor marker of IR in patients with NAFLD attributed to changes in hepatic insulin clearance (Fig. 7) . FIG. 7 . Schematic representation of how impaired hepatic insulin extraction can affect HOMA-IR measurement attributed to increased peripheral insulin. Note that although in both situations the liver is exposed to the same amount of insulin (e.g., 20 arbitrary units), peripheral insulin is different in these situations (e.g., 5 vs. 15 arbitrary units).
Whether the amount of steatosis has an important impact in other histological outcomes is a topic of intense debate. Given that clinical trials are increasingly using reduction of IHTG by magnetic resonance (MR)-based techniques as a primary outcome, it is essential to understand whether steatosis reductions translate into improvements in inflammation, ballooning, and, eventually, fibrosis. (22) (23) (24) Although, attributed to the crosssectional nature of our study, this question could not be certainly addressed, we did find that increasing amounts of IHTG were not associated with worse histology, suggesting a (partial) dissociation between the amount of steatosis and the activity of liver disease. In line with these findings, imaging studies have shown that quantification of IHTG by 1 H-MRS or other MR-based techniques could not predict the severity of histology. (5, 7, 25) Moreover, some interventional studies have shown significant improvements in steatosis without any change in inflammation, ballooning, or fibrosis. (26) Large, longitudinal studies will be needed in order to establish the true relationship between changes in IHTG and hepatocyte injury and fibrosis.
In addition, results from this study suggest that reductions in IHTG may not have the same metabolic impact across the whole range of IHTG (i.e., a relatively small reduction in IHTG from 8% to 4% may have a greater metabolic impact than a larger reduction from 16% to 8%). This is based on the fact that 6 6 2% of IHTG appears to be a marker at which most of the metabolic alterations have already been established. Therefore, significant metabolic improvement could potentially be expected with reductions of IHTG below this threshold. This, in turn, may suggest that an outcome such as proportion of patients with "resolved NAFLD" could be considered.
Taken together, our study has demonstrated that the accepted 5.56% imaging cut-off point used for the diagnosis of NAFLD has a strong metabolic correlate. In other words, $6 6 2% of IHTG is a threshold for "metabolic health." If confirmed in longitudinal studies, an IHTG content lower than 6 6 2% could be a potential threshold to aim with lifestyle intervention or pharmacological therapy, given that it associates with metabolic benefit in patients with NAFLD.
